Annie Froehlich

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley advised Vivace Therapeutics, a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, on its $35 million Series D financing.

Cooley advised DataStax, an artificial intelligence (AI) and data solution provider, on its acquisition by IBM (NYSE: IBM), a provider of global hybrid cloud and AI solutions and consulting expertise.

Cooley advised MongoDB (Nasdaq: MDB), a leading database for modern applications, on its acquisition of Voyage AI, a pioneer in state-of-the-art embedding and reranking models that power next-generation artificial intelligence applications.

Cooley advised LFX Venture Partners, a knowledge-based investor focusing on first, middle, and last-mile cutting-edge technologies and disruptive business models that drive innovation in the global value chain, on its investment in Pipe17’s $15.5 million Series A financing round. Partner Sale Kwon led the Cooley team advising LFX Venture Partners.